Eric Thomas Schmidt is CFO at Allogene Therapeutics, Inc. (ALLO). They have made 7 open-market trades across 1 company since 2020, most recently 2023-06-08.
CIK 0001754403
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALLO | SELL | 2022-03-15 | 2022-03-17 | $7.63 | $175K | +13.6% | -11.9% | +8.8% |
| ALLO | SELL | 2021-03-15 | 2021-03-17 | $38.23 | $616K | -8.3% | -9.8% | -30.5% |
| ALLO | SELL | 2021-01-14 | 2021-01-19 | $31.50 | $1.9M | +8.8% | +7.5% | +1.4% |
| ALLO | SELL | 2020-11-16 | 2020-11-18 | $32.81 | $644K | -3.9% | -18.4% | +0.3% |
| ALLO | SELL | 2020-10-15 | 2020-10-16 | $40.48 | $1.2M | -10.5% | -16.0% | -20.9% |
| ALLO | SELL | 2020-09-21 | 2020-09-22 | $35.23 | $944K | +2.1% | -1.4% | -23.4% |
| ALLO | SELL | 2020-03-16 | 2020-03-18 | $19.73 | $108K | +13.8% | +56.5% | +138.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.